NasdaqGM:RAPPPharmaceuticals
Rapport Therapeutics (RAPP) First Revenue Of US$20m Tests Bullish Growth Narratives
Rapport Therapeutics (RAPP) opened Q1 2026 with revenue of US$20 million, a basic EPS loss of US$0.42, and a net income loss of US$19.86 million, providing a clear snapshot of a company still in investment mode. Over the past year, the company has seen quarterly revenue move from US$0 to US$20 million, while quarterly basic EPS loss shifted between US$0.57 and US$0.75 before landing at US$0.42 in the latest quarter. This gives investors a clearer view of how top-line and per-share losses are...